Source: ClinicalTrials.gov — U.S. National Library of Medicine — A database of privately and publicly funded clinical studies conducted around the world (U.S. National Library of Medicine, public domain).
This page lists clinical trials related to Metabolic Disorders from the ClinicalTrials.gov database.
Trial Summary
- Total studies: 50
- Recruiting: 22
- Active, not recruiting: 6
- Completed: 14
- Other: 8
Results are refreshed periodically and may not reflect the most current information available from ClinicalTrials.gov.
Recruiting Trials
NCT00001987 — Genetic Studies of Insulin and Diabetes
| Status | Recruiting |
| Phase | N/A |
| Sponsor | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| Enrollment | 1200 |
| Study Type | OBSERVATIONAL |
| Conditions | Diabetes Mellitus; Severe Insulin Resistance |
| Interventions |
The study will allow researchers to obtain blood, plasma, DNA, and RNA for genetic studies of insulin. There will be a focus on the causes of insulin resistance and diabetes mellitus. Insulin is a hormone found in the body that controls the level of sugar in the blood. Insulin resistance refers to conditions like diabetes when insulin does not work properly. In this study researchers would like…
NCT00055172 — Genetic Basis of Immunodeficiency
| Status | Recruiting |
| Phase | N/A |
| Sponsor | National Heart, Lung, and Blood Institute (NHLBI) |
| Enrollment | 100 |
| Study Type | OBSERVATIONAL |
| Conditions | Severe Combined Immunodeficiency |
This study will examine the role of hereditary factors in different forms of severe combined immunodeficiency (SCID).
Patients with immunodeficiencies may be eligible for this study. Candidates include:
- Patients with diminished numbers of T cells or NK cells or both, or
- Patients with normal T cell and NK cell numbers but diminished T cell, B cell, or NK cell function.
Relatives of patien…
NCT00739362 — Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss Treatment
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| Enrollment | 148 |
| Study Type | INTERVENTIONAL |
| Conditions | Electric Stimulation Therapy; Obesity; Weight Loss; Eating |
| Interventions | ; |
This study will determine whether electrical stimulation of an area of the brain called the dorsolateral prefrontal cortex, which is important in determining the feeling of fullness after eating, affects how much food a person eats and weight loss over 4 weeks. It will also compare weight changes in people who attend weight loss counseling sessions and those who do not over this period of time….
NCT00341237 — Personalized Environment and Genes Study
| Status | Recruiting |
| Phase | N/A |
| Sponsor | National Institute of Environmental Health Sciences (NIEHS) |
| Enrollment | 25000 |
| Study Type | OBSERVATIONAL |
| Conditions | Diabetes; Heart Disease; Asthma |
Despite the overwhelming focus on genetic and genomic causes of human disease over the past two decades, it has been estimated that genetics is currently known to explain only 20% and 40% of the etiology of common disease. Thus, it is becoming increasingly apparent that human disease is a consequence of both genetic susceptibility and environmental exposures. Importantly, while individuals cann…
NCT01443468 — Clinical and Genetic Studies of Li-Fraumeni Syndrome
| Status | Recruiting |
| Phase | N/A |
| Sponsor | National Cancer Institute (NCI) |
| Enrollment | 5000 |
| Study Type | OBSERVATIONAL |
| Conditions | Li-Fraumeni Syndrome; Neoplasms; Tp53 Mutations |
Background:
- Li-Fraumeni syndrome (LFS) is a genetic condition that increases the risk for some types of cancer. LFS may lead to cancer of the bone or connective tissue, breast, and brain. It may also increase the risk for certain types of leukemia and other cancers. The only known cause of LFS is a change (called a mutation ) in a gene known as TP53. However, not all people with LFS have a …
NCT02089789 — Clinical and Basic Investigations Into Known and Suspected Congenital Disorders of Glycosylation
| Status | Recruiting |
| Phase | N/A |
| Sponsor | National Human Genome Research Institute (NHGRI) |
| Enrollment | 200 |
| Study Type | OBSERVATIONAL |
| Conditions | Congenital Disorders of Glycosylation |
Background:
- Proteins, fats, and other molecules are the body s building blocks. Many of these molecules must have sugars, or chains of sugars, attached to work properly. People with congenital disorders of glycosylation (CDGs) cannot attach these sugars or sugar chains properly. A child or adult with a CDG can have symptoms in different parts of the body, including brain, nerves, muscles, l…
NCT03476577 — Bariatric Surgery and Pharmacokinetics of Ibuprofen
| Status | Recruiting |
| Phase | N/A |
| Sponsor | Norwegian University of Science and Technology |
| Enrollment | 12 |
| Study Type | OBSERVATIONAL |
| Conditions | Obesity, Morbid |
| Interventions |
Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study…
NCT03497156 — Bariatric Surgery and Pharmacokinetics of Lercanidipine
| Status | Recruiting |
| Phase | N/A |
| Sponsor | Norwegian University of Science and Technology |
| Enrollment | 12 |
| Study Type | OBSERVATIONAL |
| Conditions | Obesity, Morbid |
| Interventions |
Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study…
NCT03476603 — Bariatric Surgery and Pharmacokinetics of Irbesartan
| Status | Recruiting |
| Phase | N/A |
| Sponsor | Norwegian University of Science and Technology |
| Enrollment | 12 |
| Study Type | OBSERVATIONAL |
| Conditions | Obesity, Morbid |
| Interventions |
Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study…
NCT03805919 — Men at High Genetic Risk for Prostate Cancer
| Status | Recruiting |
| Phase | N/A |
| Sponsor | National Cancer Institute (NCI) |
| Enrollment | 500 |
| Study Type | OBSERVATIONAL |
| Conditions | Prostatic Neoplasms |
Background:
Research studies have shown that genetic changes and family history may increase a man s risk for prostate cancer. Researchers want to follow the prostate health of men who have specific genetic changes associated with prostate cancer to help them learn more about which men are at higher risk for prostate cancer.
Objectives:
To study men with specific genetic changes and determin…
NCT05067179 — Analysis of Human ALS Tissues and Registry of ALS Patients
| Status | Recruiting |
| Phase | N/A |
| Sponsor | University of Illinois at Chicago |
| Enrollment | 40 |
| Study Type | OBSERVATIONAL |
| Conditions | Amyotrophic Lateral Sclerosis |
Amyotrophic Lateral Sclerosis (ALS), often referred to as Lou Gehrig’s Disease, is a progressive, terminal condition of muscle weakness that is associated with degeneration of neurons in the spinal cord and brain. This devastating disorder afflicts people in the prime of their lives. At the present time, there are no cures for this disorder, and current treatments are marginal at best. Despite …
NCT03481829 — Early Tracking of Childhood Health Determinants (ETCHED) Study
| Status | Recruiting |
| Phase | N/A |
| Sponsor | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| Enrollment | 1500 |
| Study Type | OBSERVATIONAL |
| Conditions | Diabetes Mellitus; Obesity; Fatty Liver |
Background:
Children s weight has increased sharply in recent years. This may put them at higher risk for health problems. High blood glucose in a pregnant mother and too much weight gain during pregnancy also may have long-term effects on the child s health. Children who become overweight or obese during childhood tend to remain so as adults. Researchers want to study many risk factors during…
NCT06419374 — A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | 89bio, Inc. |
| Enrollment | 762 |
| Study Type | INTERVENTIONAL |
| Conditions | Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis |
| Interventions | ; |
The study will assess the efficacy and safety of pegozafermin administered in participants with compensated cirrhosis due to MASH (biopsy-confirmed fibrosis stage F4 MASH [previously known as nonalcoholic steatohepatitis, NASH]).
NCT06694558 — Monocytes in Subjects With Type 1 Diabetes and Chronic Kidney Disease
| Status | Recruiting |
| Phase | N/A |
| Sponsor | The Cleveland Clinic |
| Enrollment | 60 |
| Study Type | OBSERVATIONAL |
| Conditions | Chronic Kidney Disease(CKD); Type 1 Diabetes (T1D) |
This is a cross-sectional study in patients with Type 1 diabetes (TID) and chronic kidney disease (CKD) to test if time in range (TIR) affects the degree of hyperglycemia required for monocyte activation, podocyte injury, and assess if monocyte activation is attenuated by glucagon-like peptide (GLP-1) agonist treatment ex vivo.
NCT06920043 — A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | GlaxoSmithKline |
| Enrollment | 42 |
| Study Type | INTERVENTIONAL |
| Conditions | Metabolic Dysfunction-Associated Steatohepatitis; Non-alcoholic Fatty Liver Disease |
| Interventions | ; |
The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of efimosfermin in participants with metabolic dysfunction associated steatohepatitis (MASH) and compensated cirrhosis consistent with stage F4 fibrosis.
NCT07355062 — A Study to Evaluate the Efficacy and Safety of Veverimer for the Treatment of Metabolic Acidosis
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Renibus Therapeutics, Inc. |
| Enrollment | 150 |
| Study Type | INTERVENTIONAL |
| Conditions | CKD; Metabolic Acidosis |
| Interventions | ; |
The purpose of this 264 week study is is to evaluate the efficacy and safety of veverimer in treating adults with moderate-to-severe chronic kidney disease (CKD) and metabolic acidosis.
NCT07689331 — Hungarian National Systemic Amyloidosis Registry
| Status | Recruiting |
| Phase | N/A |
| Sponsor | Semmelweis University |
| Enrollment | 300 |
| Study Type | OBSERVATIONAL |
| Conditions | Systemic Amyloidosis; ATTR Amyloidosis; AL Amyloidosis; Amyloid Cardiomyopathy |
This registry is an observational, multicenter, retrospective and prospective, non-pharmacological study designed to collect and analyze data from patients with systemic amyloidosis treated in inpatient and outpatient cardiology, hematology, nephrology, and neurology departments across Hungary. The registry was established in 2025.
NCT07575932 — A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1)
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Pfizer |
| Enrollment | 872 |
| Study Type | INTERVENTIONAL |
| Conditions | Overweight; Obesity; Overweight and/or Obesity; Overweight or Obesity; Overnutrition |
| Interventions | ; ; |
This study is being done to learn about the safety and effects of the study drugs, PF-08653945 and PF-08653944, when given alone or together for weight loss, compared to a placebo (a dummy drug that has no active ingredient in it).
NCT07574723 — Tirzepatide Titration to Reduce Side Effects in Individuals With Obesity
| Status | Recruiting |
| Phase | N/A |
| Sponsor | Dasman Diabetes Institute |
| Enrollment | 68 |
| Study Type | INTERVENTIONAL |
| Conditions | Obesity |
| Interventions | ; |
The goal of this clinical trial is to determine whether a flexible, symptom-guided titration strategy for tirzepatide can reduce gastrointestinal side effects while maintaining weight-loss effectiveness in adults with obesity without diabetes. The main questions it aims to answer are:
- Does flexible, symptom-guided titration reduce nausea and vomiting compared with standard per-label titrati…
NCT07191561 — Hepatic Lipid Metabolism-Alcohol Use Disorder
| Status | Recruiting |
| Phase | N/A |
| Sponsor | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| Enrollment | 25 |
| Study Type | OBSERVATIONAL |
| Conditions | Alcohol Use Disorder |
| Interventions |
Patients with hepatic steatosis due to alcohol will be offered liver biopsies when they enter a detoxification program. The first biopsy will occur in the first week of admission and the second in the fourth week when the steatosis has resolved. The hepatic transcriptome will be compared,
NCT06274749 — Effects of Urolithin A Supplementation on Glucose Metabolism in Healthy Adults 55 >= Years Old: A Randomized Triple-Masked Controlled Clinical Trial
| Status | Recruiting |
| Phase | N/A |
| Sponsor | National Institute on Aging (NIA) |
| Enrollment | 180 |
| Study Type | INTERVENTIONAL |
| Conditions | Healthy Volunteer |
| Interventions | ; |
Background:
As people age, the cells in the pancreas that produce insulin begin to release less of this hormone, and levels of blood glucose (sugar) rise. This can lead to illnesses such as diabetes. Urolithin A (UA) is a natural nutritional supplement that may improve how the body controls blood glucose.
Objective:
To learn if UA improves levels of insulin and other hormones that help contr…
NCT07521930 — Interfacing With NeuroTechnology to Expand Neural Throughput (INTENT)
| Status | Recruiting |
| Phase | N/A |
| Sponsor | Johns Hopkins University |
| Enrollment | 5 |
| Study Type | INTERVENTIONAL |
| Conditions | Tetraplegia/Tetraparesis; Amyotrophic Lateral Sclerosis (ALS); Muscular Disorders, Atrophic; Brain Stem Stroke; Spinal Cord Injuries (SCI) |
| Interventions |
The goal of this clinical trial is to evaluate the safety and preliminary efficacy of an implantable device that records and stimulates different areas of the brain to allow adults affected by disabling paralysis (see Eligibility for more details) to control and receive feedback from assistive devices.
Active, Not Recruiting
NCT01323322 — Healthy Aging in Neighborhoods of Diversity Across the Life Span (HANDLS)
| Status | Active, not recruiting |
| Phase | N/A |
| Sponsor | National Institute on Aging (NIA) |
| Enrollment | 3720 |
| Study Type | OBSERVATIONAL |
| Conditions | Diabetes; Cerebrovascular Disease; Age-Associated Decline; Cardiovascular Disease |
The Healthy Aging in Neighborhoods of Diversity across the Life Span (HANDLS) study is an interdisciplinary, community-based, prospective longitudinal epidemiologic study examining the influences of race and socioeconomic status (SES) on the development of age-related health disparities among socioeconomically diverse African Americans and whites in Baltimore. This study investigates whether he…
NCT02262832 — Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy
| Status | Active, not recruiting |
| Phase | Phase 3 |
| Sponsor | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| Enrollment | 24 |
| Study Type | INTERVENTIONAL |
| Conditions | Lipodystrophy; Diabetes; Hyperlipidemia |
| Interventions |
Background:
- Generalized lipodystrophy can cause high blood fat levels and resistance to insulin. This can lead to health problems including diabetes. Researchers have found that the drug metreleptin improves health in people with this disease.
Objective:
- To test the safety and effectiveness of metreleptin.
Eligibility:
- People ages 6 months and older with generalized lipodystrophy w…
NCT06275724 — Specified Drug-use Survey of Leqvio for s.c. Injection.
| Status | Active, not recruiting |
| Phase | N/A |
| Sponsor | Novartis Pharmaceuticals |
| Enrollment | 585 |
| Study Type | OBSERVATIONAL |
| Conditions | Familial Hypercholesterolaemia; Hypercholesterolaemia |
| Interventions |
The objective of this study is to evaluate the long-term safety of Leqvio in patients with familial hypercholesterolaemia or hypercholesterolaemia in post-marketing clinical practice
NCT06094491 — Virtual Diabetes Group Visits Across Health Systems
| Status | Active, not recruiting |
| Phase | N/A |
| Sponsor | University of Chicago |
| Enrollment | 720 |
| Study Type | INTERVENTIONAL |
| Conditions | T2DM (Type 2 Diabetes Mellitus); Hypertension; Heart Disease Chronic; Stroke; Hyperlipidemias |
| Interventions |
The purpose of this project is to evaluate the effectiveness of a virtual diabetes group visits on patients with type 2 diabetes mellitus (T2DM).
NCT06819813 — Project VIBE: Virtual Intervention for Binge Eating in Adolescents
| Status | Active, not recruiting |
| Phase | N/A |
| Sponsor | University of Pittsburgh |
| Enrollment | 50 |
| Study Type | INTERVENTIONAL |
| Conditions | Obesity; Binge-Eating Disorder; Binge Eating |
| Interventions |
The aim of this project is to pilot test a novel mobile app intervention for adolescents with dysregulated eating behaviors and elevated weight status. This intervention will incorporate evidence-informed strategies targeting self-regulation into cognitive-behavioral treatment for maladaptive eating. Adolescents will use the app for 16 weeks and provide feedback on its usability and effectivene…
NCT06976307 — Development of an Inclusive Adaptive Treatment Strategy for Weight Loss in People With Prediabetes Using a Sequential Multiple Assignment Randomized Trial
| Status | Active, not recruiting |
| Phase | N/A |
| Sponsor | University of Alabama at Birmingham |
| Enrollment | 30 |
| Study Type | INTERVENTIONAL |
| Conditions | Disabilities; Obesity and Overweight; Prediabetes |
| Interventions | ; |
This is a sub-study to NCT04745572 to include a new cohort of participants with disabilities. This 16-week study will use an experimental approach called the Sequential Multiple Assignment Randomized Trial to help determine which combination and sequence of weight loss program features are most effective in people who are at risk for type 2 diabetes. Participants in the study will be initially …
Not Yet Recruiting
NCT07690826 — A Study to Evaluate the Efficacy and Safety of HRS-4729 Injection in Obesity
| Status | Not yet recruiting |
| Phase | Phase 2 |
| Sponsor | Fujian Shengdi Pharmaceutical Co., Ltd. |
| Enrollment | 252 |
| Study Type | INTERVENTIONAL |
| Conditions | Overweight or Obesity |
| Interventions | ; ; |
This is a multicenter, randomized, double-blind, placebo-controlled Phase II study to evaluate the efficacy and safety of once-weekly HRS-4729 injection in adults with obesity without diabetes. Approximately 252 participants will be enrolled. The primary endpoint is percent change in body weight from baseline at Week 32 versus placebo.
NCT07691359 — Osteoporotic Fracture and Lidocaine Plaster 5% for Neuropathic Pain preventioN
| Status | Not yet recruiting |
| Phase | Phase 4 |
| Sponsor | University Hospital, Clermont-Ferrand |
| Enrollment | 30 |
| Study Type | INTERVENTIONAL |
| Conditions | Osteoporotic Vertebral Fracture; Neuropathic Pain |
| Interventions |
Osteoporotic vertebral fractures may lead to chronic pain with a neuropathic component, which is often underdiagnosed and undertreated in older adults. This proof-of-concept randomized controlled trial aims to evaluate whether early application of a 5% lidocaine plaster can prevent the development of neuropathic pain following an osteoporotic vertebral fracture. Participants will be randomized …
NCT06690294 — Assessing the Impact of Perceptions of Unpredictability on Objective Measures of Food Consumption and Metabolism
| Status | Not yet recruiting |
| Phase | N/A |
| Sponsor | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| Enrollment | 110 |
| Study Type | OBSERVATIONAL |
| Conditions | Healthy Volunteer; Obestity |
Background:
Many people in the United States are overweight or obese. This natural history study will look into how life events during childhood can impact eating behaviors and weight gain as adults.
Objective:
To explore how childhood experiences affect adult eating behaviors.
Eligibility:
Healthy people aged 18 to 60 years.
Design:
Participants will have 3 clinic visits.
They will be …
NCT07388537 — Evaluation of the Clinical Spectrum of Diabetes and Obesity in Youth and Adults
| Status | Not yet recruiting |
| Phase | N/A |
| Sponsor | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| Enrollment | 1000 |
| Study Type | OBSERVATIONAL |
| Conditions | Obesity; Diabetes; Metabolic Disorders |
Background:
Diabetes and obesity are chronic diseases. They can affect blood flow and how the body processes nutrients, and complications over time can lead to early death. Diabetes can affect children as well as adults, but the disease seems to be more severe and to progress faster when it appears in younger people. Researchers want to understand more about how diabetes and obesity develop an…
NCT07683065 — A Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD
| Status | Not yet recruiting |
| Phase | N/A |
| Sponsor | Novartis Pharmaceuticals |
| Enrollment | 150 |
| Study Type | OBSERVATIONAL |
| Conditions | Plaque Psoriasis; Metabolic Dysfunction-Associated Steatotic Liver Disease |
This study aims to examine the retention rate of secukinumab in adult patients with plaque psoriasis (with or without psoriatic arthritis [PsA]) and metabolic dysfunction-associated steatotic liver disease (MASLD) in routine clinical practice in Spain, as well as hepatic biomarker trajectories. The study will use electronic medical record (EMR) data from multiple Spanish hospitals.
NCT02478450 — Study to Investigate the Safety of the Transplantation (by Injection) of Human Glial Restricted Progenitor Cells (hGRPs; Q-Cells®) Into Subjects With Amyotrophic Lateral Sclerosis (ALS)
| Status | Not yet recruiting |
| Phase | Phase 1 / Phase 2 |
| Sponsor | Q Therapeutics, Inc. |
| Enrollment | 30 |
| Study Type | INTERVENTIONAL |
| Conditions | Amyotrophic Lateral Sclerosis |
| Interventions |
This study is a non-randomized, open-label, partially blinded, sequential cohort, dose-escalation study designed to obtain preliminary data on the safety, tolerability, and early efficacy of Q-Cells® transplantation in subjects with ALS. Following an initial cohort receiving cell transplants unilaterally in the lumbar spinal cord, subsequent cohorts will receive escalating doses transplanted un…
NCT07680673 — ENCRT-103-hPI: Evaluation of an Immune-protected ENCRT-103-hPI Containing Primary Human Islets in Adults With Type 1 Diabetes, With and Without Standard-of-care Portal Vein Islet Infusion.
| Status | Not yet recruiting |
| Phase | Phase 1 |
| Sponsor | Encellin |
| Enrollment | 10 |
| Study Type | INTERVENTIONAL |
| Conditions | Type 1 Diabetes |
| Interventions |
This study will evaluate the safety and performance of ENCRT-103-hPI, which is a cargo of primary islets inside Encellin’s ENC-103-CED. The 103 offers a soft pillow-like encasing to contain and protect the cells from the immune system. The product is implanted in the upper arm or abdomen and is approximately the size of a quarter. Eligibility is open to both patients on a standard of care islet…
Enrolling by Invitation
NCT00895271 — Establishing Fibroblast-Derived Cell Lines From Skin Biopsies of Patients With Immunodeficiency or Immunodysregulation Disorders
| Status | Enrolling by invitation |
| Phase | N/A |
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Enrollment | 200 |
| Study Type | OBSERVATIONAL |
| Conditions | Primary Immunodeficiency; DOCK8; Virus Susceptibility |
Background:
- National Institutes of Health (NIH) researchers have been studying immune cells (white blood cells) to better understand how the human body s defense system works and adjusts or regulates itself, and how changes in this system can make a person sick.
- To study the cells of patients who have problems with their immune systems, researchers would like to collect samples of skin cel…
Completed Trials
NCT00001813 — Examination of Clinical and Laboratory Abnormalities in Patients With Defective DNA Repair: Xeroderma Pigmentosum, Cockayne Syndrome, or Trichothiodystrophy
| Status | Completed |
| Phase | N/A |
| Sponsor | National Cancer Institute (NCI) |
| Enrollment | 709 |
| Study Type | OBSERVATIONAL |
| Conditions | Cockayne Syndrome; Skin Neoplasms; Xeroderma Pigmentosum; Trichothiodystrophy Syndromes; Genodermatosis |
Four rare genetic diseases, xeroderma pigmentosum (XP), Cockayne syndrome (CS), the XP/CS complex and trichothiodystrophy (TTD) have defective DNA excision repair although only XP has increased cancer susceptibility. We plan to perform careful clinical examination of selected patients with XP, XP/CS, CS, or TTD and follow their clinical course. We will obtain tissue (skin, blood, hair, buccal s…
NCT00040222 — Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer
| Status | Completed |
| Phase | N/A |
| Sponsor | National Cancer Institute (NCI) |
| Enrollment | 377 |
| Study Type | OBSERVATIONAL |
| Conditions | Familial Ovarian Cancer; Familial Breast Cancer; BRCA1-associate Malignancies; BRCA2-associated Malignancies |
Individuals and families with known or suspected syndromes that include breast, ovarian or genetically-related cancers are enrolled in this family study, which is a syndrome-specific sub-set of the long-standing DCEG Human Genetics Program umbrella family studies protocol (78-C-0039). Cancer outcomes are documented through review of medical, vital, and pathology records. Selected individuals an…
NCT00076830 — Evaluation and Treatment of Patients With Connective Tissue Disease
| Status | Completed |
| Phase | N/A |
| Sponsor | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
| Enrollment | 180 |
| Study Type | OBSERVATIONAL |
| Conditions | Connective Tissue Disorders; Osteogenesis Imperfecta; Bone Diseases, Metabolic; Melorheostosis |
This study offers evaluation and treatment of patients with a suspected connective tissue disorder. The protocol is not designed to test new treatments; rather, patients receive standard care. The study is designed to: 1) allow NICHD’s staff to learn more about connective tissue disorders, 2) train physicians in the evaluation and treatment of these disorders; and 3) establish a pool of patient…
NCT00523627 — Effects of Diet Changes on Metabolism
| Status | Completed |
| Phase | N/A |
| Sponsor | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| Enrollment | 203 |
| Study Type | OBSERVATIONAL |
| Conditions | Obesity |
This study, conducted at the NIH Clinical Research Unit at the Phoenix Indian Medical Center, will examine how the body s metabolism (energy expenditure) changes when people overeat and when they fast and how different diets (e.g., high-protein or high-fat) affect metabolism. The results may provide information about whether there are mechanisms that make some people more resistant than others …
NCT01498263 — Inherited Diseases, Caregiving, and Social Networks
| Status | Completed |
| Phase | N/A |
| Sponsor | National Human Genome Research Institute (NHGRI) |
| Enrollment | 682 |
| Study Type | OBSERVATIONAL |
| Conditions | Undiagnosed Disease; Healthy Volunteer (Adult With Typically Developing Child); Inherited Neurodegenerative Disorders; Inherited Metabolic Disorders (Inborn Errors of Metabolism); Alzheimer’s Disease and Related Dementias |
Approximately 66 million informal caregivers care for someone who is ill, disabled, or aged. These caregivers experience significant distress associated with caregiving, which may be particularly salient in the context of inherited conditions. Previous studies have not examined caregiving from a network perspective, nor have they considered how cognitive and emotional responses, such as caregiv…
NCT01633021 — Developing the Family Map: Looking at Communal Coping
| Status | Completed |
| Phase | N/A |
| Sponsor | National Human Genome Research Institute (NHGRI) |
| Enrollment | 1061 |
| Study Type | OBSERVATIONAL |
| Conditions | Sickle Cell; Diabetes; Cancer; Cardiovascular Disease; Genetic Screening |
Background:
- Knowing one s family medical history is a part of staying healthy. Some health risks run in families, and knowing these risks can promote more healthy behavior. Different social and cultural factors may affect how family members share this information. Genetic risk information that is shared in one family may not be shared in the same way in another. This information may also be…
NCT01934660 — Links Between Inflammation and Cardiometabolic Diseases
| Status | Completed |
| Phase | N/A |
| Sponsor | National Heart, Lung, and Blood Institute (NHLBI) |
| Enrollment | 150 |
| Study Type | OBSERVATIONAL |
| Conditions | Diabetes Mellitus; Cardiovascular Disease; Healthy Volunteer; Inflammation |
| Interventions | ; |
Background:
- Cardiometabolic diseases are a combination of medical disorders that, when they occur together, increase the risk of heart disease and diabetes. Researchers want to learn if there is a relationship between these diseases and inflammation (redness, swelling, and pain). Inflammation affects the entire body. Researchers will study this relationship in people with heart disease and …
NCT02311335 — Genes Involved in Lipid Disorders
| Status | Completed |
| Phase | N/A |
| Sponsor | National Heart, Lung, and Blood Institute (NHLBI) |
| Enrollment | 140 |
| Study Type | OBSERVATIONAL |
| Conditions | Lipid Disorders |
Background:
- Genes are the instructions our body uses to function. Researchers can look for changes, or variants, in the genes. The goal of this study is to find new gene changes that lead to lipid disorders. Older research methods looked at one or a few genes at a time. Genomic sequencing looks at most of the genes at once. Genomic sequencing may find the cause researchers haven t been able…
NCT04255433 — A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
| Status | Completed |
| Phase | Phase 3 |
| Sponsor | Eli Lilly and Company |
| Enrollment | 13299 |
| Study Type | INTERVENTIONAL |
| Conditions | Type 2 Diabetes Mellitus |
| Interventions | ; |
The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.
NCT05565534 — Diabetes Care for Breast Cancer Patients
| Status | Completed |
| Phase | N/A |
| Sponsor | Weill Medical College of Cornell University |
| Enrollment | 74 |
| Study Type | INTERVENTIONAL |
| Conditions | Breast Cancer; PreDiabetes; Type 2 Diabetes |
| Interventions |
The goal of this study is to find a new way to make diabetes care better for patients with breast cancer and diabetes who are currently receiving cancer treatment. We will have two groups, the researchers will decide who is in which group. One group will be working with a nurse who is trained in diabetes care while the other does not. This will allow the investigators to see if having a trained…
NCT05587348 — PROmoting Diabetes Education and Management Through Peer Support and Team Referral
| Status | Completed |
| Phase | N/A |
| Sponsor | University of North Carolina, Chapel Hill |
| Enrollment | 87 |
| Study Type | INTERVENTIONAL |
| Conditions | Diabetes Mellitus, Type 2 |
| Interventions | ; ; |
A 3-step project is proposed. Step 1 will test which BPA time point(s) maximize referral rates to DSMES services in the real world clinic setting (Aim 1). Step 2 will utilize that approach within a pilot study of six sites, comparing the effectiveness of peer support to improve attendance to DSMES services (Aim 2). Step 3 will engage stakeholders in designing a future large scale DSMES services…
NCT07691060 — Asprosin and Total Antioxidant/Oxidant Status in Diabetes and Periodontal Disease
| Status | Completed |
| Phase | N/A |
| Sponsor | Saglik Bilimleri Universitesi |
| Enrollment | 67 |
| Study Type | OBSERVATIONAL |
| Conditions | Periodontal Diseases; Gingival Diseases; Type 2 Diabetes |
The goal of this observational study is to learn about how different periodontal health status affects the levels of asprosin (a hormone) and total oxidant/antioxidant status in the gingival crevicular fluid and blood serum of individuals with Type 2 diabetes.
The main questions it aims to answer are:
Do individuals with Type 2 diabetes and periodontal disease have different levels of asprosi…
NCT06935838 — Effects of Tirzepatide on Weight Loss and Chronic Inflammation in People With HIV
| Status | Completed |
| Phase | Phase 2 |
| Sponsor | University of Hawaii |
| Enrollment | 12 |
| Study Type | INTERVENTIONAL |
| Conditions | Obesity and Overweight; HIV; Chronic Inflammation |
| Interventions |
This is a prospective cohort study of 12 overweight (with one or more weight-related condition) or obese adults with well controlled HIV-1 on antiretroviral therapy (ART). An initial dose of tirzepatide (TZP) 2.5 mg subcutaneous (SQ) once weekly will be given, escalated by 2.5 mg at 4-week intervals to a final dose of 7.5mg. The investigators will collect the following information via review of…
NCT07691203 — Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCl 25 mg/5 mg/1000 mg Extended Release Tablet Versus Trijardy® XR 25 mg/5 mg/1000 mg Extended- Release Tablets
| Status | Completed |
| Phase | Phase 1 |
| Sponsor | Humanis Saglık Anonim Sirketi |
| Enrollment | 36 |
| Study Type | INTERVENTIONAL |
| Conditions | Type 2 Diabetes Mellitus (T2DM); Cardiovascular Diseases |
| Interventions | ; |
An open label, randomized, two-period, two treatment, two-sequence, crossover, balanced, single dose oral bioequivalence study to compare Empagliflozin/ Linagliptin/ Metformin HCl 25 mg/5 mg/1000 mg Extended Release Tablet versus Trijardy® XR (Empagliflozin/linagliptin/metformin hydrochloride extended-release tablets 25 mg/5 mg/1000 mg) in healthy subject in fed condition.